The shift to ICH E6(R3) is forcing pharmaceutical organizations to rethink how they approach risk, oversight, and data integrity. Yet for many small and midsize sponsors, Risk-Based Quality Management (RBQM) remains difficult to interpret and even harder to implement. Conflicting advice, increasing regulatory pressure, and an oversaturated technology market have created a perception that RBQM requires large-scale transformation and complex platform ecosystems.
This whitepaper challenges that assumption. Drawing on real-world sponsor experience and IQVIA’s RBQM expertise, it demonstrates that successful implementation starts not with technology, but with people, process, and fit-for-purpose design. By focusing on protocol-driven risk assessment and scalable process frameworks, sponsors can build effective RBQM capabilities without overinvestment or unnecessary disruption.
Through practical guidance, industry insights, and a validated FSP delivery model, this paper provides a clear, achievable pathway to RBQM adoption enabling organizations to strengthen oversight, meet regulatory expectations, and drive greater value from their clinical development strategies.
The most common challenges are not technical they are organizational and strategic. These include:
These challenges often result in delayed adoption or inefficient implementation.
RBQM programs typically underperform when organizations rush to technology solutions ahead of process and expertise.
Common failure points include:
Successful RBQM requires alignment between people, process, and technology not reliance on a single component.
Protocol-driven RBQM means that risk assessment starts with Quality by Design at the protocol stage. Critical data and processes are identified early, and the protocol is designed to minimize risks where possible before the study begins. Any remaining risks are then mitigated for by targeted monitoring and oversight strategies.
This ensures that RBQM is focused on what matters most for participant safety, data quality, and study objectives, rather than being driven by technology or standardized monitoring approaches.
Most organizations require only a limited number of core capabilities, primarily to support centralized monitoring and data visualization.
Many sponsors are advised to implement multiple platforms, but this often leads to unnecessary complexity. A right-sized approach focuses on:
Technology should always reflect study scale, maturity, and operational need.
Small and midsize organizations typically face additional constraints, including:
Unlike large pharma, these organizations often cannot support large transformation programs, making scalable and flexible approaches more critical.
Enhance patient safety and study quality by using data, analytics, and technology to monitor patient, site, and study performance with risk-based and centralized monitoring.
.svg){kind=icon}
